EUVIMEDEUVIMED entdecken
Crossref

Implementing TB preventive therapy: lessons from a large-scale initiative in India

M Das, A Kalra, A S ThekkePurakkal, T Showket, S Raj, V Panibatla, D Imran, H Solanki, R Taralekar, R Rao, V Dhawan, M Parmar und 4 weitere

The International Journal of Tuberculosis and Lung Disease · 2025

DOI: 10.5588/ijtld.25.0055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2025. Verfasst von M Das und 15 weiteren Autor:innen. Beteiligte Einrichtung: FIND, New Delhi, India. Hauptthemen laut MEDLINE: Antitubercular Agents, Isoniazid, Tuberculosis, Pulmonary, Rifampin. Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

TB infection management is essential in addressing the global TB burden. TB programmes worldwide are focusing on WHO-recommended shorter duration TB preventive treatment (TPT). We document early findings of 3HP regimen (rifapentine–isoniazid weekly doses for 3 months) implementation under the Joint Effort for Elimination of Tuberculosis (JEET) project in India.





METHODS

This is a descriptive cohort study involving household contacts (HHCs) of pulmonary TB patients on TPT in select districts of the JEET project supported by FIND. The HHCs received 3HP in two districts while those in other districts received 6-month daily isoniazid (6H) during April–September 2022. The study compared characteristics, adverse events (AEs) and TPT outcomes of HHCs on 3HP with those on 6H.





RESULTS

A total of 635 HHCs were initiated on 3HP, while 24,350 HHCs received 6H. About 10% of HHCs on 3HP developed AEs compared with 4% HHCs on 6H. However, a higher proportion of HHCs on 3HP completed TPT compared with HHCs on 6H (95% vs. 84%, P < 0.001).





CONCLUSION

High TPT completion rates for 3HP with low levels of manageable AEs support expansion of 3HP under national TB programmes. The 3HP TPT regimen could be considered an effective shorter TPT option in high-TB-burden countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsIsoniazidTuberculosis, PulmonaryRifampinHumansIndiaMaleFemaleAdultCohort StudiesMiddle AgedYoung AdultAdolescentDrug Administration ScheduleDrug Therapy, Combination

Substanzen

Antitubercular AgentsIsoniazidRifampinrifapentine

Autor:innen und Institutionen

  • FIND, New Delhi, India.
  • TB Alert India, Telangana, India.
  • Karnataka Health Promotion Trust, Karnataka, India.
  • Central TB Division, WHO NTEP Technical Support Network, New Delhi, India.
  • Central TB Division, Ministry of Health and Family Welfare, New Delhi, India.
  • World Health Organization, Country Office for India, New Delhi, India.

Förderung

  • World Health Organization

Zitieren

APA

Das, M., Kalra, A., ThekkePurakkal, A. S., Showket, T., Raj, S., Panibatla, V., Imran, D., Solanki, H., Taralekar, R., Rao, R., Dhawan, V., Parmar, M., Yassin, M., Chadha, S. S., Sarin, S., & Singh, U. (2025). Implementing TB preventive therapy: lessons from a large-scale initiative in India. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.25.0055

Vancouver

Das M, Kalra A, ThekkePurakkal AS, Showket T, Raj S, Panibatla V, et al. Implementing TB preventive therapy: lessons from a large-scale initiative in India. The International Journal of Tuberculosis and Lung Disease. 2025. doi:10.5588/ijtld.25.0055

BibTeX
@article{Das2025,
  author = {Das, M and Kalra, A and ThekkePurakkal, A S and Showket, T and Raj, S and Panibatla, V and Imran, D and Solanki, H and Taralekar, R and Rao, R and Dhawan, V and Parmar, M and Yassin, M and Chadha, S S and Sarin, S and Singh, U},
  title = {Implementing TB preventive therapy: lessons from a large-scale initiative in India},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2025},
  doi = {10.5588/ijtld.25.0055}
}
Kostenlos starten →